A:

Biotech giant Amgen Inc (AMGN) bills itself as one of the first biotechnology firms. It was founded in 1980 and has grown into a firm with 20,000 employees, a market capitalization of nearly $100 billion, and approximately $20 billion in annual sales. Below is an overview of its main rivals.

Product Rivals

Any pharmaceutical or biotech firm is technically a rival to Amgen, though there is a smaller subset of rivals that sell similar drugs to Amgen. For instance, Johnson & Johnson (JNJ) sells Procrit, which is a competitor to Aranesp and Amgen’s stable of anemia treatments. Teva Pharmaceutical (TEVA) also sells an increasing array of biosimilar drugs to Aranesp Amgen’s Enbrel helps treat arthritis, which competes with AbbVie’s (ABBV) popular Humira drug. Celgene (CELG) sells Revlimid to treat myeloma and Amgen is in the process of getting into the field with the acquisition of Onyx and its Kyprolis drug, also for the treatment of myeloma.

Biotech Competition

In general, Amgen competes with other large biotech firms. Biogen Idec (BIIB) sells a number of drugs to help treat multiple sclerosis and is seeing success with the launch of a couple of drugs to treat hemophilia. Celgene sells drugs that help treat cancer and immune-inflammatory diseases. Gilead Sciences (GILD) offers a number of drugs that help patients suffering from HIV and recently released Solvadi, which has had great success in helping patients with hepatitis C infections.

The Bottom Line

A number of firms continue to muscle into Amgen’s core businesses of treating anemia, arthritis, and myeloma. Generic versions will also continue to be introduced as Amgen’s drug patents expire over time. Most investment bankers and analysts, however, still project Amgen will remain profitable over time.

At the time of writing, Ryan C. Fuhrmann is long shares of Amgen and Gilead but did not own shares in any of the other companies mentioned in this article.

RELATED FAQS
  1. What are the primary risks associated with investing in the drugs sector?

    Learn more about the primary risks facing investors in the pharmaceutical and biotechnology industries. Find out how regulation ... Read Answer >>
  2. What is the drugs sector?

    Learn more about the drug industry and how new drugs are brought to market. Find out about how drug research is financed ... Read Answer >>
  3. How does the profit margin compare for a generic drug versus a brand name drug?

    Learn how the profit margins compare for generic drugs and brand-name drugs. Brand-name drugs cost three to four times more ... Read Answer >>
  4. What does it mean that an investor faces binary outcomes when investing in drug companies?

    Learn why investments in biotech and drug companies can result in what are called binary outcomes, and understand why these ... Read Answer >>
  5. How does government regulation impact the drugs sector?

    Learn about how drugs are regulated by the U.S. government as well as the role of the Food and Drug Administration during ... Read Answer >>
  6. What are the differences between brand name drugs and generic drugs?

    Discover the process by which brand name drugs lose their patent, allowing generics to be manufactured, as well as the differences ... Read Answer >>
Related Articles
  1. Investing

    Amgen Raises 4Q Earnings Projections (AMGN)

    Amgen's 3Q earnings and revenue topped analyst estimates, thanks to cost-cutting measures.
  2. Investing

    Amgen Tops Q3 Profit Projections (AMGN)

    Aided by the decrease of expenses such as late state clinical trials, Amgen reported positive third-quarter earnings.
  3. Investing

    AMGN: How Amgen's Stock Price Rose 18.55% in 6 Months

    Amgen's stock price has outpaced biotechnology and health care ETFs over the past six months due to a solid product pipeline and rapidly increasing dividends.
  4. Investing

    Analyzing Amgen's Price & Profitability Ratios in 2016 (AMGN)

    Learn about Amgen's price ratios and profitability ratios and discover why it has one of the highest profit margins in the global pharmaceutical sector.
  5. Investing

    Amgen: An Activist Investment Analysis (AMGN)

    Learn about the activist investor campaign Third Point Partners has initiated against Amgen. Read about Third Point's criticisms of Amgen.
  6. Insights

    Amgen’s Kyprolis Fails in Trial (AMGN)

    The failure in a comparative study has raised doubts about Amgen’s $10.4 billion takeover of the drug.
  7. Investing

    If You Had Invested Right After Amgen's IPO (AMGN)

    Discover how $1,000 invested in Amgen during its initial public offering (IPO), without reinvesting dividends, would be worth over $427,000 as of November 2015.
  8. Investing

    3 Biotech Blue-Chip Companies to Keep an Eye On (AMGN, BIIB)

    Discover three blue-chip biotech stocks you should keep your eye on in 2016. Despite recent struggles in the industry, these stocks are poised for a comeback.
  9. Insights

    Long Wait for Biosimilar Amjevita (AMGN)

    While Amgen’s Humira biosimilar called Amjevita has been approved by the FDA, it will be a very long wait for real commercial benefits.
  10. Insights

    Amgen Targeting Biosimilars (AMGN)

    Amid emerging biosimilar challenges, Amgen is taking the legal route to thwart and delay competition, in addition to pursuing its own biosimilar programs.
RELATED TERMS
  1. Drug

    A substance that cures, treats, prevents or reduces the symptoms ...
  2. New Drug

    A new medication or therapy that has not been used before in ...
  3. Abbreviated New Drug Application (ANDA)

    A written request to the U.S. Food and Drug Administration to ...
  4. Abbreviated New Drug Submission (ANDS)

    A written request to Health Canada to obtain marketing approval ...
  5. Orphan Drug Credit

    A federal tax credit that provides an incentive for pharmaceutical ...
  6. Orange Book

    A list of drugs that the U.S. Food and Drug Administration has ...
COMPANIES IN THIS ARTICLE
Trading Center